FindTrial
Sign In

Clinical trial of hepatitis B drug resistance research

Analysis of multi-drug resistance and precise administration of antiviral therapy for the patients with hepatitis B

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020385
Enrollment
Unknown
Registered
2018-12-27
Start date
2018-01-01
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B

Interventions

Gold Standard:Enzyme-linked immunosorbent assay (ELISA)
Fluorescence quantitative detection of serum HBV DNA
Index test:HBV&#32
DNA&#32
resistance&#32
mutations
&#32
HBV&#32
mutation&#32
detection&#32
kit

Sponsors

Beijing Institute of Hepatology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All enrolled patients met the diagnostic criteria for chronic HBV infection in the Guidelines for Prevention and Treatment of Chronic Hepatitis B (2015), HBsAg and/or HBV DNA were positive for more than 6 months, and were judged by professional clinicians according to the patient who need antiviral therapy. Patients with first-time antiviral therapy can be enrolled, regardless of age or gender. The first dose of child-blocking patients can be selected, regardless of age.

Exclusion criteria

Exclusion criteria: Patients co-infected with HAV, HCV, HDV, and HIV will be excluded.

Design outcomes

Primary

MeasureTime frame
HBV DNA deep sequencing;—

Countries

China

Contacts

Public ContactDexi Chen

Beijing Institute of Hepatology

dexichen@ccmu.edu.cn+86 18911772483

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026